Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SAVIDA HEALTH, PC

NPI: 1598225021 · BENNINGTON, VT 05201 · Family Medicine Physician · NPI assigned 03/21/2019

$12.06M
Total Medicaid Paid
178,602
Total Claims
109,440
Beneficiaries
10
Codes Billed
2019-05
First Month
2024-12
Last Month

Provider Details

Authorized OfficialMAHONEY, MARINA (VP, REVENUE CYCLE MANAGEMENT)
NPI Enumeration Date03/21/2019

Related Entities

Other providers sharing the same authorized official: MAHONEY, MARINA

ProviderCityStateTotal Paid
SAVIDA HEALTH, PC WOODBRIDGE VA $46.54M
SAVIDA HEALTH, PC W SPRINGFIELD MA $36.21M
SAVIDA HEALTH, PC BIDDEFORD ME $3.93M
SAVIDA HEALTH, PC DOVER DE $2.76M
SAVIDA AGENCY, INC. W SPRINGFIELD MA $1.67M
SAVIDA HEALTH,PC BRISTOL TN $173K
SAVIDA AGENCY, INC. NEWARK DE $125K
SAVIDA HEALTH, PC GILFORD NH $90K
SAVIDA AGENCY, INC. BENNINGTON VT $43K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 12,782 $648K
2020 36,827 $2.45M
2021 40,849 $2.44M
2022 28,743 $2.20M
2023 36,375 $2.52M
2024 23,026 $1.80M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 121,668 67,213 $9.66M
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 24,088 17,382 $1.30M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 17,929 12,650 $593K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 7,358 6,178 $367K
99215 Prolong outpt/office vis 516 331 $51K
81025 6,365 5,099 $44K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 242 235 $18K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 273 203 $10K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 71 69 $8K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 92 80 $3K